Krü ppel-like factor 5 (KLF5) is a PY motif-containing transcription factor promoting breast cell proliferation. The KLF5 protein is rapidly degraded through the proteasome after ubiquitination by E3 ubiquitin ligases, such as WWP1 and SCF Fbw7 . In this study, we demonstrated that a transcriptional co-activator with the PDZ-binding motif (TAZ) upregulated the KLF5 expression through antagonizing the WWP1-, but not Fbw7-, mediated KLF5 ubiquitination and degradation. TAZ interacted with KLF5 through the WW domain of TAZ and the PY motif of KLF5, which is the binding site for WWP1. TAZ inhibited WWP1-KLF5 protein interaction and WWP1-mediated KLF5 ubiquitination and degradation in a WW domain-dependent manner. Overexpression of TAZ upregulated the protein levels of KLF5 and FGF-BP, which is a well-established KLF5 target gene. In addition, depletion of TAZ in both 184A1 and HCC1937 breast cells downregulated protein levels of KLF5 and FGF-BP and inhibited cell growth. Furthermore, stable depletion of either TAZ or KLF5 significantly suppressed HCC1937 xenograft growth in immunodeficient mice. Knockdown of LATS1, a TAZ upstream inhibitory kinase, up-regulated the protein levels of KLF5 and FGF-BP in 184A1 and promoted cell growth through TAZ. Finally, both KLF5 and TAZ were co-expressed in a subset of estrogen receptor a-negative breast cell lines. These results, for the first time, suggest that TAZ promotes breast cell growth partially through protecting KLF5 from WWP1-mediated degradation and enhancing KLF5#s activities.
Introduction
Krüppel-like factor 5 (KLF5) is a transcription factor highly expressed in estrogen receptor (ER)/PR/HER2 triple-negative breast cancers (1) (2) (3) . KLF5 promotes breast cell proliferation partially through a downstream gene, fibroblast growth factor binding protein 1 (FGF-BP) (4) . The KLF5 protein is ubiquitinated by WWP1 and SCF Fbw7 E3 ligases and degraded by the proteasome (2, 5) . These E3 ligases recognize the specific destruction motifs in the KLF5 transactivation domain. WWP1 interacts with KLF5 through its WW domains and the PY motif of KLF5 (5) .
The transcriptional co-activator with a PDZ-binding motif (TAZ or WWTR1) is a WW domain-containing protein negatively regulated by the Hippo tumor suppressor pathway (6) . TAZ is overexpressed in invasive breast cancer cell lines and $20% (27/126) of breast tumor samples (7) . TAZ has been shown to promote mammary epithelial cell proliferation, migration, invasion and tumorigenesis (7, 8) . As a transcriptional co-activator, TAZ interacts with multiple transcription factors, such as TEADs (9) , Smads (10), PAXs (11, 12) , TBX5 (13) , TTF-1/NKX-2.1 (14) , RUNX2 (15) and MyoD (16) . Two independent studies confirmed that TEADs mediate the oncogenic function of TAZ (6, 9) . Chan et al. (17) recently demonstrated that the WW domain of TAZ is required for TAZ to transform breast epithelial cells, suggesting that the PY motif-containing TAZ-binding partners are important for the oncogenic property of TAZ. Wbp2 has been suggested to be such a PY motif-containing TAZ-binding partner although Wbp2 is not a transcription factor (17) . The mechanism by which TAZ promotes breast cell proliferation and tumorigenesis is still not completely understood.
In the current study, we demonstrated that TAZ interacted with KLF5 through the WW domain and the PY motif and protected KLF5 from WWP1-mediated ubiquitination and degradation. Depletion of TAZ in breast cells down-regulated the expression of KLF5 and FGF-BP. Inactivation of the hippo tumor suppressor pathway by LATS1 knockdown up-regulated the KLF5 and FGF-BP expression levels through TAZ. Our results suggest that KLF5 may be the key transcription factor that interacts with the TAZ WW domain to promote breast cell proliferation and tumor growth.
Materials and methods
Cell culture and transfection HCC1937 breast cancer and 22Rv1 prostate cancer cell lines were cultured in RPMI-1640 medium (HyClone) containing 5% fetal bovine serum, 2 mM glutamine, 4.5 g/l glucose, 10 mM N-2-hydroxyethylpiperazine-N#-2-ethanesulfonic acid, 1.5 g/l sodium bicarbonate, 1 mM sodium pyruvate and 1% penicillin/streptomycin. The 184A1 and 184B5 immortalized breast epithelial cell line was cultured in Dulbecco's modified Eagle's medium/Ham's F-12 50/50 medium supplemented with 5% horse serum, 0.5 lg/ml hydrocortisone, 10 lg/ml insulin, 20 ng/ml epidermal growth factor, 0.1 lg/ml cholera enterotoxin, 2 mM glutamine and 1% penicillin/streptomycin. Breast cancer cell lines HCC1806, HCC1500, MDA-MB-134 and BT474 were purchased from ATCC and cultured under the recommended conditions. The HEK293T and TSU-Pr1 cell lines were cultured as described previously (18, 19) . Lipofectamine TM 2000 (Invitrogen, Carlsbad, CA) was used for transfection of Small interfering RNA (siRNA) and plasmid constructs.
RNA interference
The siRNA (shRNA) target sequences used in this study are: 5#-GGAUACAG-GAGAAAACGCA-3# (TAZ siRNA#1/shRNA); 5#-AAACACCCAUGAA-CAUCAA-3# (TAZ siRNA#2); 5#-CGAUUACCCUGGUUGCACA-3# (KLF5 siRNA/shRNA); 5#-GCCUUGCAGGAAAUUCGAA-3# (LATS1 siRNA#1); 5#-CCUCCAUACGAGUCAAUCA-3# (LATS1 siRNA#2) and 5#-CUUACG-CUGAGUACUUCGA-3# (Luciferase siRNA/shRNA). All siRNAs were synthesized by Applied Biosystems/Ambion (Austin, TX) and were transected with final concentration at 10 nM. The pSIH1-H1-puro lentiviral shRNA vector was used to express the Luc, TAZ and KLF5 shRNA in HCC1937. Puromycin (1 lg/ml) was used to select drug-resistant cell populations.
Stable TAZ overexpression
Flag-tagged wild type (WT) TAZ, WW domain deleted TAZ (TAZ-nWW) and TAZ-S89A [gifts from Dr Jeffrey L. Wrana at the University of Toronto (10)] were subcloned into the pBabe-puro retroviral vector. All plasmids were transfected into AMP293 packaging cells, and retroviruses were collected at 72 h after transfection to transduce TSU-Pr1 target cells. Forty-eight hours later, 2 lg/ml puromycin was added for selecting drug-resistant cell populations.
Quantitative reverse transcription-polymerase chain reaction Quantitative reverse transcription-polymerase chain reaction was performed as described in our previous study (2) .
Antibodies
The WWP1 and KLF5 antibodies (Abs) have been described in our previous study (2) . The anti-TAZ rabbit polyclonal (#2149) and anti-LATS1 (C66B5) rabbit monoclonal (#3477) Abs are from Cell Signaling Technology (Danvers, MA). The mouse anti-TAZ Ab used in immunofluorescence staining is from BD Biosciences (#560235). anti-HA (Y-11) rabbit polyclonal (sc-805) Ab is from Santa Cruz Biotechnology (Santa Cruz, CA). The FGF-BP mouse monoclonal Ab (MAB1593) is from R&D Systems (Minneapolis, MN). Western blot, immunoprecipitation, immunofluorescence staining, GST pull-down and KLF5 ubiquitination assays were performed as described previously (5) .
Cell proliferation and viability assays 184A1 and HCC1937 cell proliferation and cell viability were measured by the 3 H-thymidine incorporation assay and Sulphorhodamine B (SRB) assay respectively, as described previously (4, 20) .
Tumorigenesis in severe combined immunodeficiency mice Eighteen 4-to 5-week-old NOD severe combined immunodeficiency (SCID) mice were purchased from Charles River (Wilmington, MA). The mice were randomly distributed equally into three groups (Lucsh, TAZsh and KLF5sh, six mice per group). Each mouse was injected subcutaneously at the third pair of mammary glands with a mixture of tumor cells (5.0 Â 10 6 cells per site in 100 ll phosphate-buffered saline) and Matrigel (1:1; Life Sensor). Tumor volumes were measured twice a week and calculated as 1/2 Â length Â width 2 . All the mice were killed at day 42, and tumor wet weights were measured.
Results
TAZ interacted with KLF5 in a WW domain-and PY motif-dependent manner HEK293T cells were co-transfected with WT KLF5 and Flag-tagged TAZ and a WW domain-deleted TAZ mutant (TAZ-nWW). Flag-TAZ proteins were immunoprecipitated with anti-Flag M2 beads. A strong co-immunoprecipitation between KLF5 and WT TAZ was detected ( Figure 1A ). TAZ-nWW did not pull-down KLF5 efficiently. Reciprocal immunoprecipitation was performed with Flag-tagged WT KLF5, KLF5nPY [a KLF5 mutant without the PY motif (5)] and endogenous TAZ in HEK293T cells. When KLF5-3ÂFlag was immunoprecipitated with anti-Flag M2 beads, endogenous TAZ was only coimmunoprecipitated with WT KLF5, but not KLF5nPY ( Figure 1B) . Additionally, the WW domain of TAZ, like the first WW domain of WWP1, is sufficient to interact with KLF5, as determined by the GST pull-down assay ( Figure 1C ). Furthermore, the interaction between endogenous TAZ and KLF5 proteins was detected in HCC1937 cells ( Figure 1D ). KLF5 is a nuclear protein (5), whereas TAZ can localize in both the cytoplasm and nucleus. By immunofluorescence staining, we demonstrated that endogenous KLF5 and TAZ co-localized in the nucleus of 184A1 breast cells ( Figure 1E ). These results indicate that TAZ interacted with KLF5 in a WW domain-and PY motif-dependent manner.
TAZ protected KLF5 from WWP1-mediated ubiquitination and proteasomal degradation Since both WWP1 and TAZ interact with KLF5 through WW/PY motifs, we asked if TAZ decreases the interaction between WWP1 and KLF5. Indeed, when WT TAZ was co-expressed with Myc-WWP1C886S (a catalytic inactive mutant) and KLF5-3ÂFlag in HEK293T cells, the KLF5-associated WWP1 was obviously decreased (Figure 2A ). Under the same conditions, TAZ-nWW did not decrease the binding between WWP1 and KLF5 ( Figure 2A ). These results suggest that TAZ could reduce the WWP1-KLF5 protein interaction in a WW domain-dependent manner.
To test whether TAZ prevents KLF5 from WWP1-mediated ubiquitination, 22Rv1 cells were co-transfected with KLF5, WWP1 and Flag-tagged TAZ or TAZ-nWW. Compared with the vector control, WWP1 overexpression dramatically increased the KLF5 ubiquitination ( Figure 2B ). The WWP1-mediated KLF5 ubiquitination was almost completely blocked by the overexpression of WT TAZ, but not TAZ-nWW ( Figure 2B ). Similar experiments were performed with Myc-Fbw7c. TAZ did not reduce the Fbw7c-mediated KLF5 ubiquitination (Supplementary Figure 1A is available at Carcinogenesis Online).
To further test whether TAZ prevents KLF5 from WWP1-mediated degradation, a cycloheximide (CHX) chase experiment was performed to measure the decay rate of the KLF5 protein by WWP1 in HEK293T cells. Compared with the vector control, TAZ dramatically elevated the steady KLF5 protein level and extended the KLF5 protein half-life ( Figure 2C ). TAZ-nWW had no significant effect on the KLF5 stability ( Figure 2C ). These results demonstrated that the WW domain of TAZ is essential for protecting KLF5 from WWP1-induced degradation. Consistent with the ubiquitination results, TAZ did not protect KLF5 from Fbw7c-mediated degradation (Supplementary Figure 1B is available at Carcinogenesis Online). Actually, WWP1 and Fbw7 independently target KLF5 for ubiquitin-mediated degradation through recognizing different destruction motifs in KLF5. In the Fbw7-deficient HCT116 cells, WWP1 still increased KLF5 ubiquitination in an E3 ligase activity-dependent manner (Supplementary Figure 2A is available at Carcinogenesis Online). Additionally, knockdown of WWP1 and Fbw7 additively increased the KLF5 protein levels in 184A1 cells (Supplementary Figure 2B is available at Carcinogenesis Online). TAZ specifically prevented WWP1-, but not Fbw7-, mediated KLF5 degradation.
To test whether endogenous TAZ stabilizes KLF5, TAZ was knocked down by two different anti-TAZ siRNAs in 184A1 cells. When TAZ was depleted, the KLF5 protein levels were decreased ( Figure 2D ). As expected, the KLF5 messenger RNA levels were not decreased by TAZ siRNAs (data not shown). MG132, a proteasome inhibitor, rescued the decrease of KLF5 by TAZ siRNAs, indicating that TAZ protected KLF5 from degradation by the 26S proteasome.
To test whether TAZ regulates KLF5#s function, WT TAZ, TAZnWW and TAZ-S89A [a constitutive nuclear localized TAZ mutant (10)] were stably overexpressed in TSU-Pr1 bladder cancer cells, in which the function of KLF5 has been established (19) . In our previous study, overexpression of KLF5 has been shown to up-regulate the FGF-BP gene expression in TSU-Pr1 cells (19) . As a result, TAZ-WT, TAZ-nWW and TAZ-S89A showed no obvious effect on the FGF-BP expression levels in the absence of KLF5 ( Figure 2E ). In KLF5-overexpressing K12 cells, overexpression of WT TAZ specifically increased the KLF5 and FGF-BP protein levels compared with the vector control and TAZ-nWW. As expected, the constitutive active TAZ-S89A increased the KLF5 and FGF-BP protein levels more efficiently compared with WT TAZ ( Figure 2E ). By quantitative reverse transcription-polymerase chain reaction , we demonstrated that the FGF-BP messenger RNA levels were upregulated by TAZ and TAZ-S89A by $4-and 20-fold, respectively in K12 cells (Supplementary Figure 3 is available at Carcinogenesis Online). At the same time, the KLF5 messenger RNA levels were not affected by TAZ and TAZ-S89A in V4 cells (supplementary Figure 3 is available at Carcinogenesis Online). These results suggest that TAZ increased KLF5 transcriptional activities after stabilizing the KLF5 protein.
Knockdown of TAZ decreased the KLF5 and FGF-BP expression and suppressed breast cell proliferation In our previous study (4) , KLF5 has been demonstrated to promote breast cell proliferation through up-regulating the expression of FGF-BP. Since knockdown of endogenous TAZ decreased the KLF5 expression levels in 184A1 ( Figure 2D ), we wondered whether TAZ depletion would down-regulate the FGF-BP expression and breast cell proliferation. Similar to the knockdown of KLF5, the knockdown of TAZ decreased the FGF-BP protein level ( Figure 3A ) and significantly decreased cell proliferation in 184A1, as measured by the DNA synthesis and SRB assays ( Figure 3B ). Similar results were observed in the HCC1937 breast cancer cell line ( Figure 3C and D) . These results suggest that endogenous TAZ increases the expression of KLF5 and FGF-BP and promotes breast cell proliferation.
Stable depletion of TAZ and KLF5 suppressed breast tumorigenesis
To provide proof-of-concept evidence that inhibition of TAZ or KLF5 suppresses breast cancer in vivo, TAZ and KLF5 were stably silenced in HCC1937 by shRNAs, respectively ( Figure 4A ). Consistent with the previous results using siRNA, stable knockdown of TAZ and KLF5 down-regulated the FGF-BP protein levels and significantly . TAZ (green) was localized in both the nucleus and the cytoplasm. KLF5 (red) was predominately located in the nucleus. The yellow color in the merged three-dimensional image indicates a cell with nuclear co-localized KLF5 and TAZ. The top and side bars of the merged image represent the XZ and YZ axes, respectively. Nuclear DNA (blue) was stained with 4#,6-diamidino-2-phenylindole.
TAZ stabilizes the KLF5 protein decreased the cell growth ( Figure 4B and C) . Importantly, the tumorigenesis assay in SCID mice showed that depletion of either TAZ or KLF5 dramatically suppressed the xenograft growth ( Figure 4D ). The tumor weights of HCC1937-TAZsh and -KLF5sh were significantly (P , 0.01) less than that of HCC1937-Lucsh at day 42 ( Figure 4E ). Depletion of TAZ and depletion of KLF5 showed similar effects in terms of tumor suppression.
LATS1 suppressed the expression of KLF5 and FGF-BP and breast cell growth through TAZ TAZ is well known to be suppressed by LATS kinases (8) . To test whether KLF5 is also regulated by LATS1/2 and contributes to the Hippo tumor suppressor pathway, LATS1 was transiently knocked down by two different siRNAs in 184A1 ( Figure 5A ). Indeed, knockdown of LATS1 up-regulated the protein levels of KLF5 and FGF-BP. In contrast, knockdown of LATS2 did not increase the KLF5 and FGF-BP protein levels in 184A1 (Supplementary Figure 4 is available at Carcinogenesis Online). To further determine whether the upregulation of the KLF5 and FGF-BP expression by LATS1 silencing is through TAZ, TAZ and LATS1 were knocked down simultaneously in 184A1. Indeed, the up-regulation of KLF5 and FGF-BP expression by the LATS1 siRNA was abrogated when TAZ was silenced together ( Figure 5B ). As the positive control, knockdown of KLF5 completely blocked the FGF-BP expression regardless of the LATS1 and TAZ expression statuses.
LATS1 is a tumor suppressor whose expression is down-regulated in aggressive breast cancer due to the promoter methylation (21) . Knockdown of LATS1 in 184A1 up-regulated the KLF5 and FGF-BP expression; therefore, it is very likely that cell proliferation will be increased by LATS1 depletion. We measured the cell viability by the SRB assay and found that LATS1 silencing indeed modestly increased the cell viability of 184A1 ( Figure 5C ). To determine whether LATS1 functions through the TAZ-KLF5 pathway, we silenced TAZ and KLF5 with LATS1 together. As shown in Figure 5C , the LATS1 siRNA-induced cell growth increase was blocked by the knockdown of either TAZ or KLF5. These findings not only reveal that LATS1 promotes cell growth through TAZ and KLF5 but also suggest that KLF5 may contribute to the Hippo tumor suppressor pathway.
TAZ and KLF5 were co-expressed in ER-negative breast cell lines KLF5 is highly expressed in ERa-negative breast cell lines (4) . TAZ has been reported to be over-expressed in a subset of invasive breast cancer cell lines and $20% of breast tumors (7). Since TAZ stabilized the KLF5 protein in breast cells, we asked whether both proteins are (B) TAZ decreased the WWP1-induced KLF5 ubiquitination. The ubiquitination assay was performed in 22Rv1 cells as described in our previous study (5) . The goat anti-KLF5 Ab was used for IP under a denaturing condition. The KLF5 ubiquitination was blocked by the overexpression of TAZ, but not the TAZ-nWW mutant. (C) TAZ, but not the TAZ-nWW, elevated the steady levels of KLF5 and extended the KLF5 protein half-life in the presence of WWP1 over-expression. The half-lives of KLF5 were measured by the cycloheximide (CHX, 50 lg/ml) chase assay and western blot. The lower panel shows the quantitative band intensities normalized by GST. (D) Endogenous TAZ protected the KLF5 protein from proteasomal degradation. The luciferase (Luc) siRNA was used as the negative control for two different TAZ siRNAs. MG132 (10 lM), a 26S proteasome inhibitor, was used to treat the cells overnight before harvest. The numbers below the KLF5 panel are the quantitative normalized band intensities for KLF5. (E) Over-expression of TAZ, but not TAZ-nWW, increased the protein levels of KLF5 and its downstream target gene FGF-BP. TAZ, TAZ-nWW, TAZ-S89A and an empty vector were stably transduced into two stable KLF5 isogenic TSU-Pr1 cell clones, V4 and K12 (19) . TAZ and TAZ-S89A increased both the KLF5 and FGF-BP levels only in K12, but not in V4.
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co-expressed in breast cell lines. By western blot ( Figure 6A) , we examined the protein levels of TAZ and KLF5 in seven breast cell lines. There is a positive expression correlation between KLF5 and TAZ in these cell lines. Both are highly expressed in ER-negative cell lines (184B5, 184A1, HCC1937 and HCC1806) but lowly expressed in ER-positive breast cancer cell lines (HCC1500, MDA-MB-134 and BT474). These expression patterns support the hypothesis that TAZ stabilizes KLF5 in breast cells.
Discussion
The KLF5 PY motif seems to play a dual role for KLF5 protein stability. KLF5 is an oncogenic transcription factor in several cancer types including breast cancer (4) and intestinal cancer (22) . We previously demonstrated that the KLF5 protein is rapidly degraded by the proteasome after ubiquitination by WWP1 (5). KLF5 recruits WWP1 through the PY motif in the KLF5 transactivation domain (5) . However, the positive regulation of KLF5 at the posttranslational level in breast cancer is largely unknown. Here, we discovered that KLF5 interacted with TAZ through the PY motif (Figure 1) . TAZ specifically antagonized the WWP1-, but not Fbw7-, mediated KLF5 ubiquitination and degradation. In addition to WWP1 and TAZ, other WW domain-containing proteins may also regulate the KLF5 protein degradation. The abundance of different WW domaincontaining KLF5-binding partners may work together to determine the KLF5 protein expression level and activity.
KLF5 is very likely suppressed by the Hippo tumor suppressor pathway. TAZ is a transcriptional co-activator in the Hippo pathway (6) . The LATS kinase mediated TAZ phosphorylation at S89 and S311 leads to TAZ sequestration in the cytoplasm (8) and proteasomal degradation (23) . Knockdown of LATS1 in 184A1 up-regulated the KLF5 and FGF-BP protein levels in a TAZ-dependent manner ( Figure 5) . Additionally, the knockdown of KLF5 blocked the LATS1 siRNA-induced cell growth, indicating that KLF5 contributes to the Hippo tumor suppressor pathway ( Figure 6B ). Thus, KLF5 is involved in multiple cancer signaling pathways, such as the Ras-mitogenactivated protein kinase (24), Wnt-b-catenin (22) , transforming growth factor b-Smad (25) and Hippo pathways. How different signals coordinately regulate the KLF5 activity needs further investigation.
Stabilization of KLF5 by TAZ is a novel mechanism for TAZ to promote breast cell growth. KLF5 promotes breast cell proliferation (4). We found that TAZ and KLF5 showed similar pro-proliferative TAZ stabilizes the KLF5 protein functions in breast cells. KLF5 promotes breast cell proliferation partially through upregulating the transcription of FGF-BP (2, 4, 26) . Manipulation of TAZ expression in different cell models regulated the expression of both KLF5 and FGF-BP. TAZ has been shown to alter the expression of other KLF5 downstream target genes, such as NANOG, OCT4 (10, 27) and PDGFA (28, 29) , in other cell models. It is worth pointing out that TAZ promotes cell proliferation partially through stabilizing KLF5 because TAZ may primarily functions through TEADs (9) . Additionally, TAZ also functions through other PY motif-containing proteins, such as Wbp2 (17) , RUNX2 (15) and MyoD (16) , as well as other non-PY motif-containing proteins, such as TBX5 (13) .
Both TAZ and KLF5 may play important role in stem cell selfrenewal and differentiation. KLF5 has been shown to promote the self-renewal of embryonic stem cells (ESCs) and to maintain ESCs in an undifferentiated state by regulating the expression of key pluripotency genes, such as Nanog (27) and Oct3/4 (30) . Similarly, TAZ has been reported to be required to maintain ESC self-renewal ÃÃ P , 0.01 (t-test for the data collected at the final day). (E) Stable knockdown of either TAZ or KLF5 significantly decreased tumor weights compared with the Lucsh control.
ÃÃ P , 0.01 (t-test).
through regulating transforming growth factor b signaling and loss of TAZ leads to differentiation (10) . Furthermore, TAZ has been shown to play a significant role in mesenchymal stem cell differentiation (15) . Interestingly, the gene expression signature of basal-like breast cancer cells is similar to that of ESCs as shown through analyzing the microarray data from 1211 tumors (3). KLF5 and eight other genes are highly expressed in grad3/ERa-basal-type poorly differentiated breast tumors (3). Most recently, we found that KLF5 contributes to progesterone-induced breast cell dedifferentiation (31) . Whether the TAZ-KLF5 axis contributes to breast cancer stem cell self-renewal and differentiation need further investigation. Both KLF5 and TAZ appear to be expressed in invasive breast cancers. KLF5 is highly expressed in ER/PR/HER2 triple-negative breast tumors and associated with poor prognosis (1,3) . Similarly, TAZ was shown to be overexpressed in invasive breast cancer cell lines and $20% of breast tumors (7) . Consistent with the published results, we found that the protein expression patterns of KLF5 and TAZ are similar in a panel of breast cell lines ( Figure 6 ). Several Hippo components, NF2, Sav (WW45) and Mats (Mob), are mutated in human tumors (32) . Interestingly, a missense mutation (F229V) of-TAZ/WWTR1 was identified in a basal-like breast cancer (33) . Whether this mutation increases the TAZ function or not is unknown.
We sequenced the coding region of TAZ in five breast cancer cell lines, including HCC1937, HCC1806, SUM149, BT549 and HCC1500, and found no mutations in these samples (data not shown). Therefore, the mutation of TAZ may be infrequent in breast cancer.
The xenograft growth of HCC1937 in SCID mice was dramatically inhibited by the stable knockdown of either TAZ or KLF5 (Figure 4) . The inhibitory effects in vivo are much more striking than the effects on cell growth in vitro. One potential reason is that KLF5 and FGF-BP are well established to promote angiogenesis (34, 35) , which only occurs in vivo. These results not only suggest that KLF5 and TAZ promote tumorigenesis but also imply that they are potential therapeutic targets for basal type breast cancers. TAZ knockout mice have been reported to have defects in the kidney and lung (28) . Interestingly, KLF5 knockout mice also showed defects in the lung development (36) . Whether KLF5 plays a role in TAZ knock-out mice needs to be elucidated.
In summary, we demonstrated that TAZ interacted with the KLF5 protein through the WW domain and PY motif, specifically attenuated the WWP1-, but not Fbw7-, mediated KLF5 degradation and increased the KLF5 activities of inducing FGF-BP gene expression and promoting breast cell proliferation. Our findings suggest that TAZ, as the key effector of the Hippo tumor suppressor pathway, 
